Colorectal Cancer Dataset in Xijing Hospital From 2011
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- Recruiting
- Fourth Military Medical University
-
Contact:
- Jipeng Li
- Phone Number: +86-029-84771533
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 1. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
- 2. Visit our center with complete medical records and pathological information;
- 3. Colorectal cancer patients diagnosed between 2013 and 2023.
Exclusion Criteria:
- 1. The patient has other colorectal malignancies other than adenocarcinoma;
- 2. Malignant tumors adjacent to organs invading the colon and rectum;
- 3. Malignant tumors from distant organs metastasize to the colon and rectum;
- 4. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
colorectal cancer
Colorectal cancer patients are enrolled when patients were underwent surgeries.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall survival
Time Frame: from date of diagnosis until the date of death from any cause, assessed up to 120 months
|
to dead or lost to follow
|
from date of diagnosis until the date of death from any cause, assessed up to 120 months
|
|
DFS
Time Frame: from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months
|
disease-free survival
|
from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRC dataset
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.